Managing cardiometabolic risk: An evolving approach to patient care

Critical Pathways in Cardiology

Volumn 6, Issue 1, 2007, Pages 5-14

  Watson, Karol ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abdominal adiposity; Cardiometabolic risk; Metabolic syndrome

Indexed keywords

CYTOKINE; FAT; GLUCOSE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ECONOMIC ASPECT; ENDOCRINE GLAND; GLUCOSE METABOLISM; HEALTH CARE COST; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SUBCUTANEOUS FAT;

ABDOMINAL FAT; ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; INSULIN RESISTANCE; OBESITY; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 33947149504     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hpc.0000255063.43838.6d     Document Type: Article

References (60)

1. American Heart Association. Heart disease and stroke statistics-2005 update. 2005.
2. National Diabetes Information Clearinghouse. National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed November 10, 2005.
3. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
4. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-776.
5. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449.
6. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
7. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
8. McKenna MT, Michaud CM, Murray CJ, et al. Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med. 2005;28:415-423.
9. Wang G, Zheng ZJ, Heath G, et al. Economic burden of cardiovascular disease associated with excess body weight in U.S. adults. Am J Prev Med. 2002;23:1-6.
10. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
11. Pescatello LS, VanHeest JL. Physical activity mediates a healthier body weight in the presence of obesity. Br J Sports Med. 2000;34:86-93.
12. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
13. Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone. 2001;4:17-23.
14. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. 1999;WHO/NCD/NCS/99.2.
15. International Diabetes Federation. The IDF consensus worldwide definition of metabolic syndrome. Available at: http://www.idf.org/webdata/docs/ IDF_Metasyndrome_definition.pdf. Accessed November 3, 2005.
16. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diabetes Rep. 2005;5:70-75.
17. National Heart, Lung, and Blood Institute. What is high blood pressure? Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_WhatIs.html. Accessed November 7, 2005.
18. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
19. American Diabetes Association and National Institute of Diabetes and Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.
20. American Diabetes Association. Frequently asked questions about prediabetes. Available at: http://www.diabetes.org/pre-diabetes/faq.jsp. Accessed November 28, 2005.
21. American Heart Association. What's the difference between LDL and HDL cholesterol? Available at: http://www.americanheart.org/presenter-.jhtml? identifier=180. Accessed November 28, 2005.
22. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-1778.
23. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
24. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108:1546-1551.
25. Meigs JB. The metabolic syndrome. BMJ. 2003;327:61-62.
26. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.
27. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement executive summary. Circulation. 2005;112:e285-e290.
28. Meigs JB, D'Agostino RB, Wilson PW, et al. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes. 1997;46:1594-1600.
29. Hanley AJ, Festa A, D'Agostino RB, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004;53:1773-1781.
30. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
31. Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954-1961.
32. Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the renin-angiotensin- aldosterone system, and the heart. Arch Intern Med. 2004;164:1737-1748.
33. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129-180.
34. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908-914.
35. ob mice. Int J Obes. 2005;29:183-187.
36. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-431.
37. Deprés JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716-720.
38. National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The practical guide identification, evaluation, and treatment of overweight and obesity in adults. NHLBI obesity education initiative. 2000. NIH Publication Number 00-4084.
39. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition. 2005;21:969-976.
40. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest. 2002;32(Suppl 3):14-23.
41. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
42. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes. 2002;26(Suppl 4):S5-S7.
43. Zhu S, Wang Z, Heshka S, et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76:743-749.
44. Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res. 2002;10:923-931.
45. Wang Y, Rimm EB, Stampfer MJ, et al. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555-563.
46. Lakka HM, Lakka TA, Tuomilehto J, et al. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J. 2002;23:706-713.
47. Vasan RS, Pencina MJ, Cobain M, et al. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med. 2005;143:473-480.
48. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
49. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
50. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442-2450.
51. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
52. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
53. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-1063.
54. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893-2898.
55. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005-2010.
56. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004;89:2697-2703.
57. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
58. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
59. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
60. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-259.